Physician profile
Michael Kuo
NPI 1033593744
$5,387.43
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $750 · 2020: $74.96 · 2021: $1,477 · 2022: $1,171 · 2023: $1,746 · 2024: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,889 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,889.27 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,060.64 | 2020-2024 | Mounjaro, Trulicity, Jardiance |
| Dexcom, INC. | $925.46 | 2021-2024 | Dexcom G6 Transmitter |
| Pfizer INC. | $767.57 | 2019-2023 | |
| Novo Nordisk INC | $565.79 | 2021-2023 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $259.87 | 2021-2022 | |
| Abbvie INC. | $147.48 | 2021-2023 | |
| Horizon Therapeutics Plc | $144.14 | 2022-2023 | Tepezza |
| Amgen INC. | $138.87 | 2020-2023 | Prolia, Evenity |
| Embecta Corp. | $126.16 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.18 | 2021-2023 | Jardiance |
| Becton, Dickinson and Company | $110.47 | 2022 | |
| Ascensia Diabetes Care US INC. | $87.14 | 2021-2023 | |
| Mannkind Corporation | $85.46 | 2021-2022 | |
| Corcept Therapeutics | $78.89 | 2021-2023 | Korlym |
| Radius Health, INC. | $73.35 | 2023 | Tymlos |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $58.11 | 2021-2022 | |
| Rhythm Pharmaceuticals, INC. | $57.29 | 2022-2023 | Imcivree |
| Grt US Holding, INC. | $55.46 | 2022 | |
| Sanofi-Aventis U.S. LLC | $49.68 | 2023 | |
| Amarin Pharma, INC. | $48.49 | 2022 | |
| Xeris Pharmaceuticals, INC. | $45.76 | 2022-2023 | Gvoke Hypopen |
| Currax Pharmaceuticals LLC | $38.94 | 2022-2023 | Nexletol |
| Esperion Therapeutics, INC. | $34.42 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.44 | 2021 | |
| Averitas Pharma INC. | $31.11 | 2023 | Qutenza |
| Ibsa Pharma INC. | $28.04 | 2021-2023 | Tirosint, Licart |
| Recordati_rare_diseases_inc. | $26.38 | 2023 | Signifor Lar, Isturisa |
| Medtronic, INC. | $25.49 | 2023 | Minimed 780g |
| Lifescan, INC. | $24.69 | 2023 | |
| Cequr Corporation | $24.21 | 2023 | Cequr Simplicity |
| Bigfoot Biomedical INC | $21.45 | 2022 | |
| Zealand Pharma US, INC. | $21.28 | 2021 | |
| Kyowa Kirin, INC. | $20.65 | 2023 | Crysvita |
| Antares Pharma, INC. | $20.20 | 2021 | |
| Insulet Corporation | $17.13 | 2023 | Omnipod |
| Abbott Laboratories | $11.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kuo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.